Parkinson's Trial NCT04888364
Help slow Parkinson disease progression
- Trial ID
- NCT04888364
- Official Title
- Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
- Goal
- Help slow Parkinson disease progression
- Status
- RECRUITING
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Study Type
- OBSERVATIONAL
- Enrollment
- 30000 participants
- Conditions
- Parkinson Disease
Summary For Families
Goal: Gather long-term clinical, genetic, imaging, and biological data across France to better understand how Parkinson's and related parkinsonian disorders begin, progress, and vary between people, and to identify early risk markers. Approach: People join an observational cohort with regular clinical exams and optional biosamples like blood and skin biopsy plus imaging when available, so researchers can link symptoms to biological and genetic clues; no experimental drug is given and usual treatments such as levodopa are continued as needed. Eligibility: Open to anyone age 10 and up who is covered by French social security and who has Parkinson's, another parkinsonian syndrome, or is at increased risk (for example a relative of a patient, a known PD gene carrier, or someone with idiopathic REM sleep behavior disorder), provided they can give informed consent and are not under legal protection.
Locations
- Centre 01 Paris, Paris, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. Goal: Gather long-term clinical, genetic, imaging, and biological data across France to better understand how Parkinson's and related parkinsonian disorders begin, progress, and vary between people, and to identify early risk markers. Approach: People join an observational cohort with regular clinical exams and optional biosamples like blood and skin biopsy plus imaging when available, so researchers can link symptoms to biological and genetic clues; no experimental drug is given and usual treatments such as levodopa are continued as needed. Eligibility: Open to anyone age 10 and up who is covered by French social security and who has Parkinson's, another parkinsonian syndrome, or is at increased risk (for example a relative of a patient, a known PD gene carrier, or someone with idiopathic REM sleep behavior disorder), provided they can give informed consent and are not under legal protection.
- Who can participate?
- Participants must be at least 10 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 7 years.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.